CPT® Code 90679

The CPT® Code 90679 refers to a specific vaccine designed to provide active, long-term immunity against respiratory syncytial virus (RSV). This vaccine is a recombinant, subunit formulation that includes a stabilized version of the virus's prefusion F glycoprotein, known as RSVPreF3. This glycoprotein is crucial for the virus's ability to enter host cells, making it a key target for the immune response. By introducing this altered version of the virus into the body, the vaccine stimulates the immune system to produce antibodies that can recognize and combat RSV upon future exposure. RSV is a highly contagious virus that primarily affects infants and young children, but it can also pose significant risks to older adults, individuals with compromised immune systems, and those with underlying health conditions such as diabetes, congestive heart failure, asthma, or chronic obstructive pulmonary disease (COPD). Infections caused by RSV can lead to severe respiratory illnesses, including pneumonia, which may require hospitalization and can be fatal. The vaccine is administered intramuscularly and is particularly important for adults in higher risk categories, as it enhances their immune response through the use of a proprietary adjuvant. It is important to note that this code specifically reports the vaccine product itself and does not include the administration of the vaccine.